Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671182 | 1.00 | P4HB (0.43) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL7144664 | 0.80 | PTPN1 (0.58) | CA12CA2CA3CA6CA9 | |
| SCHEMBL7144667 | 0.80 | PTPN1 (0.58) | CA12CA2CA3CA6CA9 | |
| SCHEMBL1260529 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL21574805 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL1687911 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL1687898 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL8699093 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL13799049 | 0.77 | FBP1 (0.59) | P4HBNR1H3FBP1CA12CA2 | |
| SCHEMBL574156 | 0.77 | MAOB (0.47) | ALDH1A1LMNAMAPTL3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4425628-B2 | — | — | 2010-03-03 | — | — | JP | claimed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | claimed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | claimed |
| JP-2005505519-A | — | — | 2005-02-24 | — | — | JP | claimed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106014-A1 | Methods for treating diabetes | ALOX5, ALOX15, ALOX15B | P4HB 1603/4885NR1H3 770/4885FBP1 412/4885 |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | P4HB 741/4885NR1H3 618/4885FBP1 4612/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | P4HB 741/4885NR1H3 618/4885FBP1 4612/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | P4HB 741/4885NR1H3 618/4885FBP1 4612/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | P4HB 741/4885NR1H3 618/4885FBP1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.